 - Patients 9 to 18 years of age who completed visit 33 week 104 of WA19977 study with at least JIA ACR30 clinical response to RoActemraActemra relative to baseline in WA19977, with no AEs, SAEs or conditions that lead to unacceptable risk of continued treatment 